DUBLIN, Jan. 10, 2024 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, today announced that the Board of Directors has declared a quarterly cash dividend of $0.615 per share on outstanding Class A Ordinary Shares. The dividend is payable February 15, 2024 to shareholders of record on February 1, 2024.
About Aon
Aon plc (NYSE: AON) exists to shape decisions for the better ? to protect and enrich the lives of people around the world. Our colleagues provide our clients in over 120 countries and sovereignties with advice and solutions that give them the clarity and confidence to make better decisions to protect and grow their business.
In line with their commitment to upholding the highest standards of transparency, below is the Adani Portfolio's Credit and Result compendium for financial year 2023-24.
The performance in FY24 and the past five years signify the strength and...
Linker Vision, a pioneer in AI technology, is proud to announce a collaboration with NVIDIA aimed at accelerating vision AI adoption across enterprise applications with large vision models (LVMs). Through this collaboration, Linker Vision is poised...
ConcertAI, the leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration with NVIDIA to advance a broad set of translational and clinical development solutions within the ConcertAI CARA AI platform....
Vention, the company behind the cloud-based Manufacturing Automation Platform (MAP), today announced a collaboration with NVIDIA to bring industrial automation technology to small and medium manufacturers by using NVIDIA AI and accelerated computing...
Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) in frontline non-small cell lung...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
